Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of “Hold” from Brokerages

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $85.5833.

HSIC has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Barclays initiated coverage on Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 price target on the stock. Mizuho lifted their price objective on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their target price on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Morgan Stanley upped their target price on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday, February 25th.

Henry Schein Stock Performance

Shares of HSIC stock opened at $73.94 on Monday. Henry Schein has a one year low of $60.56 and a one year high of $89.29. The company’s 50-day moving average is $76.87 and its 200 day moving average is $73.43. The company has a market capitalization of $8.48 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts expect that Henry Schein will post 4.74 EPS for the current fiscal year.

Insider Activity

In related news, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total value of $228,543.84. Following the sale, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Mark E. Mlotek sold 5,925 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the completion of the sale, the executive vice president directly owned 80,554 shares of the company’s stock, valued at approximately $6,508,763.20. This trade represents a 6.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 105,911 shares of company stock valued at $8,574,982 over the last three months. Corporate insiders own 1.08% of the company’s stock.

Institutional Trading of Henry Schein

Several large investors have recently modified their holdings of the company. Artisan Partners Limited Partnership boosted its position in Henry Schein by 5.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after purchasing an additional 370,837 shares during the last quarter. Invesco Ltd. increased its position in shares of Henry Schein by 4.1% during the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock valued at $314,043,000 after purchasing an additional 184,763 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Henry Schein by 8.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,816,317 shares of the company’s stock worth $212,865,000 after purchasing an additional 220,149 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Henry Schein by 11.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock worth $167,453,000 after purchasing an additional 256,156 shares during the period. Finally, Southpoint Capital Advisors LP boosted its holdings in shares of Henry Schein by 38.9% in the fourth quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock worth $188,950,000 after buying an additional 700,000 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.